Etiology

Disease states that trigger systemic activation of coagulation may lead to disseminated intravascular coagulation (DIC). Causes include:​[1][2]​[6][7]

  • Sepsis/severe infection, including severe coronavirus disease 2019 (COVID-19) infection[3]

  • Major trauma or burns

  • Some malignancies (acute myelocytic leukemia or metastatic mucin-secreting adenocarcinoma)

  • Obstetric disorders (amniotic fluid embolism, eclampsia, abruptio placentae, retained dead fetus syndrome)

  • Severe organ destruction or failure (severe pancreatitis, acute hepatic failure)

  • Vascular disorders (Kasabach-Merritt syndrome or giant hemangiomas, large aortic aneurysms)

  • Severe toxic or immunologic reactions (blood transfusion reaction or hemolytic reactions, organ transplant rejection, snake bite).

DIC induced by these causes may be acute or chronic.

Acute DIC is more common with rapid-onset underlying conditions such as major trauma, sepsis/severe infection, and massive blood transfusion.

Chronic DIC is more common with less acute disorders such as malignancies, paroxysmal nocturnal hemoglobinuria, and Raynaud disease. Localized DIC (characterized by bleeding or thrombosis limited to a specific anatomic location) is associated with an underlying disorder such as aortic aneurysm, giant hemangioma, and hyperacute renal allograft rejection.​[1][2]

Pathophysiology

Two important hallmarks of DIC are continuous generation of intravascular fibrin and consumption/depletion of procoagulants and platelets.[8] Increased clotting is accompanied by decreased fibrinolysis. Thrombin production is increased by activation of the extrinsic tissue factor (VIIa) pathways.[9] Thrombin, a proteolytic enzyme, cleaves fibrinogen to form fibrin. Without the functional counteraction from the anticoagulant pathways, increased thrombin continuously amplifies the coagulation cascade through its positive feedback and consumptive depletion of procoagulants and platelets, finally leading to widespread fibrin deposition, resulting in multiorgan failure.

A coexisting mechanism in the development of DIC relates to the impaired fibrinolytic system, which includes tissue factor pathway inhibitor, antithrombin III, and the protein C system. Plasmin, which degrades fibrin into measurable fibrin degradation products, is a key component of the fibrinolytic system. The impaired fibrinolytic system probably results from decreased production of plasmin due to a sustained increase in plasma level of plasminogen activator inhibitor type I (PAI-I).

Another mechanism involves the mutual potentiation between the inflammatory and coagulation pathways. A systemic inflammatory response can activate the coagulation pathways by activating the cytokine network. Interleukin-6 and tumor necrosis factor are cytokines that activate the coagulation pathway. Because activated protein C has an anti-inflammatory effect through its inhibition of cytokine production, depression of protein C promotes inflammation, which favors coagulation. In addition, the products produced by coagulation, such as factor Xa, thrombin, and fibrin, activate endothelial cells to release proinflammatory cytokines. Thus, both coagulation and inflammatory pathways positively reinforce each other, forming a vicious circle and causing uncontrolled activation of systemic coagulation.​[1][2]

Classification

DIC subtypes[1]

  • Acute DIC is characterized by rapid-onset generalized bleeding and microcirculatory/macrocirculatory thrombosis, resulting in hypoperfusion, infarction, and end-organ damage.

  • Chronic DIC is characterized by subacute bleeding and diffuse thrombosis.

In addition to clinical classification as acute/chronic subtypes, the International Society on Thrombosis and Haemostasis recommends classifying DIC as overt or non-overt. Overt DIC refers to a decompensated hemostatic system, whereas non-overt DIC refers to a stressed but compensated hemostatic system.[4]

Use of this content is subject to our disclaimer